Quantifying the relationship between sub-population wastewater samples and community-wide SARS-CoV-2 seroprevalence
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.04.28.22274086: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources 2.4 Estimating COVID-19 prevalence based on community seroprevalence testing: Serostatus was determined as a qualitative assessment by measuring levels of SARS-CoV-2 spike protein specific immunoglobulin (Ig) G (Spike IgG) antibodies in peripheral blood samples as reported previously by Hamorsky et al.24 Seroprevalence can detect the antibodies of COVID-19 patients up to 300 days following infection.25,26 There was a low number of participants positive for Spike IgG antibodies for the individual areas of MSD3, MSD4 and MSD5 (MSD3-5 N=31 participants positive) (Table 1). SARS-CoV-2 spike protein …SciScore for 10.1101/2022.04.28.22274086: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources 2.4 Estimating COVID-19 prevalence based on community seroprevalence testing: Serostatus was determined as a qualitative assessment by measuring levels of SARS-CoV-2 spike protein specific immunoglobulin (Ig) G (Spike IgG) antibodies in peripheral blood samples as reported previously by Hamorsky et al.24 Seroprevalence can detect the antibodies of COVID-19 patients up to 300 days following infection.25,26 There was a low number of participants positive for Spike IgG antibodies for the individual areas of MSD3, MSD4 and MSD5 (MSD3-5 N=31 participants positive) (Table 1). SARS-CoV-2 spike protein specific immunoglobulin (Ig) G (Spike IgGsuggested: NoneSpike IgGsuggested: NoneMSD5suggested: NoneResults from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
